ReviewJournal of proteome research2025
Identifying Links between Alzheimer's Disease and Type 2 Diabetes through Proteomics.
Review in Journal of proteome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular and cellular processes connecting type 2 diabetes to Alzheimer's disease, focusing on oxidative stress, metabolic dysfunction, and neurodegeneration.Genetics and molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alzheimer's disease (AD) and type 2 diabetes (T2D) are both amyloidogenic, age-associated chronic diseases and their occurrences are linked by epidemiological evidence and common dysregulated molecular functions including glucose hypometabolism, dyslipidemias, and altered insulin signaling. High-throughput molecular profiling of the genome and transcriptome has advanced our understanding of their molecular links; however, proteomic signatures may reveal novel biomarkers and additional insights because proteins are the primary purveyors of molecular function. Herein, the contributions to our understanding of the molecular links between AD and T2D by high-throughput proteomics are reviewed. Collectively, the studies highlight strong, but broad, common molecular and metabolic signatures; however, more investigation is needed to define shared mechanisms and identify robust biomarkers and potential therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.